FY2024 EPS Estimate for Xeris Biopharma Raised by Analyst

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) – Equities researchers at HC Wainwright boosted their FY2024 earnings estimates for shares of Xeris Biopharma in a note issued to investors on Monday, November 11th. HC Wainwright analyst O. Livnat now anticipates that the company will post earnings per share of ($0.41) for the year, up from their previous estimate of ($0.42). HC Wainwright has a “Buy” rating and a $6.60 price objective on the stock. The consensus estimate for Xeris Biopharma’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Xeris Biopharma’s Q4 2024 earnings at ($0.07) EPS, FY2025 earnings at ($0.29) EPS, FY2026 earnings at ($0.03) EPS and FY2028 earnings at $0.51 EPS.

Separately, Piper Sandler cut shares of Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 target price for the company. in a research note on Monday.

Xeris Biopharma Stock Performance

XERS stock opened at $3.15 on Wednesday. Xeris Biopharma has a one year low of $1.46 and a one year high of $3.64. The stock has a market capitalization of $469.60 million, a PE ratio of -7.00 and a beta of 2.70. The company has a fifty day moving average of $2.99 and a 200-day moving average of $2.53.

Institutional Trading of Xeris Biopharma

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in shares of Xeris Biopharma by 7.3% in the first quarter. Vanguard Group Inc. now owns 7,606,242 shares of the company’s stock valued at $16,810,000 after purchasing an additional 519,897 shares during the period. Rosalind Advisors Inc. increased its holdings in Xeris Biopharma by 10.6% during the 2nd quarter. Rosalind Advisors Inc. now owns 3,120,170 shares of the company’s stock valued at $7,020,000 after acquiring an additional 300,000 shares in the last quarter. Renaissance Technologies LLC increased its holdings in Xeris Biopharma by 33.9% during the 2nd quarter. Renaissance Technologies LLC now owns 1,351,640 shares of the company’s stock valued at $3,041,000 after acquiring an additional 342,300 shares in the last quarter. AQR Capital Management LLC increased its holdings in Xeris Biopharma by 4.6% during the 2nd quarter. AQR Capital Management LLC now owns 1,193,080 shares of the company’s stock valued at $2,684,000 after acquiring an additional 52,074 shares in the last quarter. Finally, Invenomic Capital Management LP increased its holdings in Xeris Biopharma by 6.3% during the 1st quarter. Invenomic Capital Management LP now owns 604,512 shares of the company’s stock valued at $1,336,000 after acquiring an additional 35,893 shares in the last quarter. Institutional investors and hedge funds own 42.75% of the company’s stock.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.